Exploration of efficacy and bleeding with combined phosphoinositide 3-kinase β inhibition and aspirin in man

Journal of Thrombosis and Haemostasis

Volumn 13, Issue 8, 2015, Pages 1494-1502

  Nylander, S ^a   Wagberg F ^a   Andersson, M ^a   Skarby T ^a   Gustafsson, D ^a,b  

^a ASTRAZENECA R AND D   (Sweden)

^b Emeriti Pharma   (Sweden)

Author keywords

Acetylsalicylic acid; Antiplatelet agents; Bleeding; P2Y12 receptor antagonists; PI 3 kinase

Indexed keywords

ACETYLSALICYLIC ACID; ADENOSINE DIPHOSPHATE; CLOPIDOGREL; COLLAGEN; CYCLOOXYGENASE 1; PHOSPHATIDYLINOSITOL 3 KINASE; PHOSPHATIDYLINOSITOL 3 KINASE INHIBITOR; PHOSPHOINOSITIDE 3 KINASE BETA; PURINERGIC P2Y12 RECEPTOR; THROMBIN RECEPTOR ACTIVATING PEPTIDE; TICAGRELOR; UNCLASSIFIED DRUG; [1 (7 METHYL 2 MORPHOLIN 4 YL 4 OXO 4H PYRIDO[1,2 A]PYRIMIDIN 9 YL)ETHYLAMINO]BENZOIC ACID; 2-(1-(7-METHYL-2-MORPHOLIN-4-YL-4-OXO-4H-PYRIDO(1,2-A)PYRIMIDIN-9-YL)ETHYLAMINO)BENZOIC ACID; ADENOSINE; ANTHRANILIC ACID DERIVATIVE; ANTITHROMBOCYTIC AGENT; P2RY12 PROTEIN, HUMAN; PROSTAGLANDIN SYNTHASE INHIBITOR; PROTEIN KINASE INHIBITOR; PTGS1 PROTEIN, HUMAN; PURINERGIC P2Y RECEPTOR ANTAGONIST; PYRIMIDINONE DERIVATIVE;

ADULT; ANIMAL EXPERIMENT; ANTIPLATELET EFFECT; ARTICLE; BLEEDING; BLEEDING TIME; CONCENTRATION RESPONSE; CONTROLLED STUDY; CROSSOVER PROCEDURE; CUTANEOUS BLEEDING TIME; DOG; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG EFFECT; DRUG EFFICACY; DRUG POTENCY; DRUG POTENTIATION; DRUG SAFETY; DRUG WITHDRAWAL; ENZYME INHIBITION; EPISTAXIS; EX VIVO STUDY; HUMAN; HUMAN CELL; HUMAN EXPERIMENT; IN VITRO STUDY; LOADING DRUG DOSE; MALE; MONOTHERAPY; NONHUMAN; NORMAL HUMAN; OPEN STUDY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SKIN BRUISING; THROMBOCYTE AGGREGATION INHIBITION; VIRAL GASTROENTERITIS; ANALOGS AND DERIVATIVES; ANIMAL; ANIMAL MODEL; ANTAGONISTS AND INHIBITORS; BLOOD; BLOOD CLOTTING PARAMETERS; CHEMICALLY INDUCED; COMBINATION DRUG THERAPY; DRUG EFFECTS; ENZYMOLOGY; SWEDEN; THROMBOCYTE; THROMBOCYTE AGGREGATION; YOUNG ADULT;

ADENOSINE; ADULT; ANIMALS; ASPIRIN; BLOOD PLATELETS; CROSS-OVER STUDIES; CYCLOOXYGENASE 1; CYCLOOXYGENASE INHIBITORS; DOGS; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG THERAPY, COMBINATION; HEMORRHAGE; HUMANS; MALE; MODELS, ANIMAL; ORTHO-AMINOBENZOATES; PHOSPHATIDYLINOSITOL 3-KINASE; PLATELET AGGREGATION; PLATELET AGGREGATION INHIBITORS; PLATELET FUNCTION TESTS; PROTEIN KINASE INHIBITORS; PURINERGIC P2Y RECEPTOR ANTAGONISTS; PYRIMIDINONES; RECEPTORS, PURINERGIC P2Y12; SWEDEN; YOUNG ADULT;

EID: 84937971229     PISSN: 15387933     EISSN: 15387836     Source Type: Journal    
DOI: 10.1111/jth.13027     Document Type: Article

References (15)

1. Nylander S, Kull B, Björkman JA, Ulvinge JC, Oakes N, Emanuelsson BM, Andersson M, Skärby T, Inghardt T, Fjellström O, Gustafsson D. Human target validation of phosphoinositide 3-kinase (PI3K)β: effects on platelets and insulin sensitivity, using AZD6482 a novel PI3Kβ inhibitor. J Thromb Haemost 2012; 10: 2127-36.
2. Jackson SP, Robertson AD, Kenche V, Thompson P, Prabaharan H, Anderson K, Abbott B, Goncalves I, Nesbitt W, Schoenwaelder S, Saylik D. Preparation of morpholinyl- and pyridinyl-substituted heterobicyclic ketones as selective inhibitors of phosphoinositide 3-kinase ß for use against thrombosis. PCT Int Appl. 2004; WO2004016607.
3. Yusuf S, Zhao F, Mehta SR, Chrolavicius S, Tognoni G, Fox KK, Clopidogrel in Unstable Angina to Prevent Recurrent Events Trial Investigators. Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation. N Engl J Med 2001; 345: 494-502.
4. Wiviott SD, Braunwald E, McCabe CH, Montalescot G, Ruzyllo W, Gottlieb S, Neumann FJ, Ardissino D, De Servi S, Murphy SA, Riesmeyer J, Weerakkody G, Gibson CM, Antman EM, TRITON-TIMI 38 Investigators. Prasugrel versus clopidogrel in patients with acute coronary syndromes. N Engl J Med 2007; 357: 2001-15.
5. Wallentin L, Becker RC, Budaj A, Cannon CP, Emanuelsson H, Held C, Horrow J, Husted S, James S, Katus H, Mahaffey KW, Scirica BM, Skene A, Steg PG, Storey RF, Harrington RA, Freij A, Thorsén M; PLATO Investigators. Ticagrelor versus clopidogrel in patients with acute coronary syndromes. N Engl J Med 2009; 361: 1045-57.
6. Bonaca MP, Bhatt DL, Cohen M, Steg PG, Storey RF, Jensen EC, Magnani G, Bansilal S, Fish MP, Im K, Bengtsson O, Ophuis TO, Budaj A, Theroux P, Ruda M, Hamm C, Goto S, Spinar J, Nicolau JC, Kiss RG, et al. Long-term use of ticagrelor in patients with prior myocardial infarction. N Engl J Med. 2015; 372: 1791-800.
7. Yeh RW, Kereiakes DJ, Steg PG, Windecker S, Rinaldi MJ, Gershlick AH, Cutlip DE, Cohen DJ, Tanguay JF, Jacobs A, Wiviott SD, Massaro JM, Iancu AC, Mauri L; DAPT Study Investigators. Benefits and risks of extended duration dual antiplatelet therapy after PCI in patients with and without acute myocardial infarction. J Am Coll Cardiol. 2015; 65: 2211-21.
8. Tricoci P, Huang Z, Held C, Moliterno DJ, Armstrong PW, van de Werf F, White HD, Aylward PE, Wallentin L, Chen E, Lokhnygina Y, Pei J, Leonardi S, Rorick TL, Kilian AM, Jennings LH, Ambrosio G, Bode C, Cequier A, Cornel JH, et al. Thrombin-receptor antagonist vorapaxar in acute coronary syndromes. N Engl J Med. 2012; 366: 20-33.
9. Morrow DA, Braunwald E, Bonaca MP, Ameriso SF, Dalby AJ, Fish MP, Fox KA, Lipka LJ, Liu X, Nicolau JC, Ophuis AJ, Paolasso E, Scirica BM, Spinar J, Theroux P, Wiviott SD, Strony J, Murphy SA, TRA 2P-TIMI 50 Steering Committee and Investigators. Vorapaxar in the secondary prevention of atherothrombotic events. N Engl J Med 2012; 366: 1404-13.
10. Ni J, Liu Q, Xie S, Carlson C, Von T, Vogel K, Riddle S, Benes C, Eck M, Roberts T, Gray N, Zhao J. Functional characterization of an isoform-selective inhibitor of PI3K-p110β as a potential anticancer agent. Cancer Discov 2012; 2: 425-33.
11. Bowie EJ, Owen CA Jr. Standardization of the bleeding time. Scand J Haematol Suppl 1980; 37: 87-94.
12. van Giezen JJ, Berntsson P, Zachrisson H, Björkman JA. Comparison of ticagrelor and thienopyridine P2Y(12) binding characteristics and antithrombotic and bleeding effects in rat and dog models of thrombosis/hemostasis. Thromb Res 2009; 124: 565-71.
13. Folts J. An in vivo model of experimental arterial stenosis, intimal damage, and periodic thrombosis. Circulation 1991; 6(suppl): IV3-14.
14. 12 receptor blockade supplied by either ticagrelor or prasugrel. J Thromb Haemost 2011; 10: 2103-5.
15. Jackson SP, Schoenwaelder SM, Goncalves I, Nesbitt WS, Yap CL, Wright CE, Kenche V, Anderson KE, Dopheide SM, Yuan Y, Sturgeon SA, Prabaharan H, Thompson PE, Smith GD, Shepherd PR, Daniele N, Kulkarni S, Abbott B, Saylik D, Jones C, et al. PI 3-kinase p110beta: a new target for antithrombotic therapy. Nat Med 2005; 11: 507-14.